Skip to main content
Normal View

Vaccination Programme

Dáil Éireann Debate, Thursday - 29 April 2021

Thursday, 29 April 2021

Questions (113)

Peadar Tóibín


113. Deputy Peadar Tóibín asked the Minister for Health when those under 16 years of age with complex medical needs including their in-home caregivers will receive the vaccine in circumstances in which it has been medically supported by a consultant such as in the case of a person (details supplied). [22380/21]

View answer

Written answers (Question to Health)

The COVID-19 Vaccine Allocation Strategy sets out a provisional list of groups for vaccination. The Strategy was developed by the National Immunisation Advisory Committee (NIAC) and the Department of Health, endorsed by the National Public Health Emergency Team (NPHET), and approved by Government on 8 December 2020. 

On the 23rd of February, the Minister for Health announced an update to Ireland’s COVID-19 Vaccine Allocation Strategy. In comprising the initial Vaccine Allocation Strategy, the NIAC listed several conditions associated with increased risk of severe disease and death. In the intervening period, national and international evidence has become available which has enabled a more detailed analysis of underlying conditions that may increase the risk of developing severe disease or death. The NIAC has now been able to more comprehensively identify those medical conditions and to distinguish between those which place a person at very high or high risk of severe disease if they contract the virus. Medical conditions and the magnitude of the risk they pose will continue to be monitored and periodically reviewed.  

On the 30th of March, the Government approved a further update to the COVID-19 Vaccination Allocation Strategy. Based on clinical, scientific and ethical frameworks produced by the National Immunisation Advisory Committee and the Department of Health, following the vaccination of those most at risk, future groups will be vaccinated by age, in cohorts of 10 years (i.e., 64-55; 54-45, etc.). 

The move to an age-based model better supports the programme objectives by: 

- protecting those at highest risk of severe disease first, which benefits everyone most; 

- facilitating planning and execution of the programme across the entire country; 

- improving transparency and fairness. 

Further details are available here:

No vaccine has currently been approved for ages younger than 16 years.